generic glp-1 2024 FDA Approves First Weight Loss Drug Hims & Hers Expands GLP-1

Every compounded GLP-1 that is replaced by a generic/branded product is a win for drug safety

231 In non-randomized interventions, FIM therapies are associated with BMI reductions of 0.4 to 0.6 kg/m 2

This results in the release of certain chemicals such as histamine, which cause signs of an allergic reaction

This includes factors such as your body mass index (BMI), current health status, medical history, lifestyle, and weight loss goals

Several other commonly used drugs like lisinopril, warfarin, metformin, digoxin, ethinyloestradiol/levonorgestrel, rosuvastatin and furosemide have been evaluated but no clinically relevant change in the exposure of semaglutide has been seen in drugdrug interaction studies [Figure 5]